Proteomic Analysis of Androgen-Independent prostate cancer

雄激素非依赖性前列腺癌的蛋白质组学分析

基本信息

项目摘要

We studied comprehensive protein expression of androgen-independent(AI) prostate cancer by means of an agarose two-dimensional electrophoresis (agarose 2-DE) method followed by liquid chromatography-tandem mass spectrometry system. The agarose 2-DE method being good at separating high-molecular-mass(HMM) proteins and alkaline ones, so we were able to successfully reveal differences between proteomes of androgen-dependent tumors and those of AI tumors. During the creation of agarose 2-DE protein maps, we successfully identified 295 proteins (91.0%) out of 324 spots excised in total. Excluding redundant and mouse-serum proteins, we considered remaining 225 proteins to be related to the cancer. We divided the 225 cancer-related proteins into HMM and low-molecular-mass(LMM) groups by their molecular mass being above or below 80 kDa. Functional classification of the proteins in these two groups showed clear differences between the two : more than half (54.8%) of the HMM proteins, but less than one-third (29.1%) of the LMM ones were classified among transcription- or translation-related proteins.Eighteen proteins were regulated when the tumor progressed from an AD to an AI state. Five of these proteins, including antioxidant protein 2,superoxide dismutase 1, thioredoxin peroxidase, GTP-binding protein beta chain homolog, and the ha1225 gene product, had a function to protect cells against oxidant stress-induced apoptosis. We suggest that prevention against oxidative stress is one of the key points for prostate cancer to obtain androgen independency. We also found proteins that had not been previously reported in prostate cancer by use of genomic or conventional 2-DE-based proteomic approaches. The proteomic approach, using agarose 2-DE focused on HMM proteins, has the capability to find novel biomarkers of prostate cancer.
采用琼脂糖凝胶双向凝胶电泳法(琼脂糖凝胶双向凝胶电泳法)结合高效液相色谱-串联质谱仪对雄激素非依赖性前列腺癌(AI)的蛋白质表达进行了研究。琼脂糖凝胶双向凝胶电泳法能够很好地分离高分子量蛋白质和碱性蛋白质,因此我们能够成功地揭示雄激素依赖型肿瘤和AI肿瘤蛋白质组之间的差异。在琼脂糖凝胶2-DE蛋白质图谱的创建过程中,我们成功地在总共324个切除点中鉴定了295个蛋白质(91.0%)。排除多余的蛋白质和小鼠血清蛋白质,我们认为剩余的225个蛋白质与癌症有关。我们根据分子质量大于或小于80 kDa将225个癌症相关蛋白分为HMM和LMM两个组。这两组蛋白质的功能分类显示出明显的差异:超过一半(54.8%)的HMM蛋白质属于转录或翻译相关蛋白质,而LMM蛋白质中不到三分之一(29.1%)属于转录或翻译相关蛋白质。当肿瘤从AD发展到AI状态时,18种蛋白质受到调控。其中5种蛋白质,包括抗氧化蛋白2、超氧化物歧化酶1、硫氧还蛋白过氧化物酶、GTP结合蛋白β链同源物和ha1225基因产物,具有保护细胞免受氧化应激诱导的细胞凋亡的功能。我们认为,预防氧化应激是前列腺癌获得雄激素非依赖性的关键之一。我们还通过使用基因组或传统的基于2-DE的蛋白质组学方法发现了以前在前列腺癌中没有报道的蛋白质。蛋白质组学方法,使用琼脂糖2-DE专注于HMM蛋白质,有能力找到前列腺癌的新生物标记物。

项目成果

期刊论文数量(46)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Delayed recovery of urinary continence after laparoscopic radical prostatectomy.
腹腔镜根治性前列腺切除术后尿失禁恢复延迟。
Weekly paclitaxel plus estramustine combination therapy in Horumone-refractory prostate cancer : A pilot study
每周紫杉醇加雌莫司汀联合治疗激素难治性前列腺癌:一项试点研究
Delayed recovery of urinary continence after laparoscopic radical prostatectomy
腹腔镜前列腺癌根治术后尿失禁延迟恢复
  • DOI:
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Egawa S;Kuruma H;Suyama K;Iwamura M;Baba S.
  • 通讯作者:
    Baba S.
車 英俊, 頴川 晋他: "前立腺癌をめぐるコンセンサスと論点-PSAおよび関連パラメータの取り扱い"癌と化学療法. 30(1). 11-15 (2002)
Hidetoshi Kuruma、Susumu Tokawa 等人:“前列腺癌的共识和问题 - PSA 和相关参数的处理”,Cancer and Chemotherapy 30(1) (2002)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
PSAおよび関連パラメーターの取り扱い
PSA及相关参数的处理
  • DOI:
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    車 英俊;頴川 晋
  • 通讯作者:
    頴川 晋
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EGAWA Shin其他文献

EGAWA Shin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EGAWA Shin', 18)}}的其他基金

A search for prostate cancer-specific genes
寻找前列腺癌特异性基因
  • 批准号:
    11671579
  • 财政年份:
    1999
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Search for molecular marker for predicting progression in prostate cancer by competitive PCR analysis
通过竞争性 PCR 分析寻找预测前列腺癌进展的分子标记
  • 批准号:
    08671841
  • 财政年份:
    1996
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation on molecular markers for assessment of biological activity in prostate cancer
前列腺癌生物活性评估分子标志物的研究
  • 批准号:
    05807146
  • 财政年份:
    1994
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Novel chelators for Scandium-44 in PET imaging of prostate cancer
用于前列腺癌 PET 成像的新型 Scandium-44 螯合剂
  • 批准号:
    2904564
  • 财政年份:
    2024
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Studentship
Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 1.86万
  • 项目类别:
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
  • 批准号:
    479295
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Operating Grants
Histopathology image analysis for prostate cancer prognosis after radical prostatectomy
前列腺癌根治术后预后的组织病理学图像分析
  • 批准号:
    478494
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Operating Grants
Urinary Phthalate Biomarker Concentrations and Breast and Prostate Cancer Risk in a National Cohort of Adults in Canada
加拿大全国成人队列中尿液邻苯二甲酸盐生物标志物浓度与乳腺癌和前列腺癌风险
  • 批准号:
    494953
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Operating Grants
Artificial Intelligence assisted mapping of prostate cancer progression in patient biopsies with novel tissue labelling biomarkers - beyond Gleason Sc
人工智能利用新型组织标记生物标志物辅助绘制患者活检中前列腺癌进展图 - 超越格里森科学
  • 批准号:
    2887602
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Studentship
Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
使用模拟禁食饮食进行间歇性禁食以改善前列腺癌控制和代谢结果
  • 批准号:
    10639416
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer
RNA m6A修饰在前列腺癌发病及耐药中的作用及机制
  • 批准号:
    10638634
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
FOXA1 通过 ARID1A 调节前列腺癌中的细胞因子信号传导和免疫景观
  • 批准号:
    10681898
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
DYRK1B Inhibition for Prostate Cancer
DYRK1B 抑制前列腺癌
  • 批准号:
    10665942
  • 财政年份:
    2023
  • 资助金额:
    $ 1.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了